Research progress on biological indexes which predict the efficiency of neoadjuvant chemotherapy for breast cancer_CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Authors：

TAN Longtao , TENG Xiaofei , CHENG Kai , WANG Xiaohong , LIU Jian , ZHANG Yingzhe ,  YANG Zhenlin

Thyroid and Breast Surgery, Binzhou Medical University Hospital, Binzhou, Shandong 256600, P. R. China;

Corresponding?author：

YANG Zhenlin, Email: Yangzhenlin918@163.com

Keywords：

breast cancer; neoadjuvant chemotherapy; biological indexes; pathological complete response; review

DOI：

10.7507/1007-9424.201704012

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To summarize the progress of biological indexes which could predict the efficiency of neoadjuvant chemotherapy for breast cancer. Methods Various related researches were collected to make a review. Results Many indexes linked to the efficiency of neoadjuvant chemotherapy for breast cancer according to several studies. According to many studies, indexes such as human epidermal growth factor receptor-2 (HER-2) gene, estrogen receptor (ER), progesterone receptor (PR), Ki-67, P53 gene, neutrophil to lymphocyte ratio (NLR), platelet level, and mean platelet volume (MPV) may have association with the outcome of neoadjuvant chemotherapy in treatment of breast cancer, and these factors maybe individual biomarkers to predict the efficiency of the treatment, but no coincident conclusion has been reached for these indexes. Conclusion The value of these indexes that predict the efficiency of neoadjuvant chemotherapy is not sure, further study need to be done to solve this topic.

Citation： TAN Longtao, TENG Xiaofei, CHENG Kai, WANG Xiaohong, LIU Jian, ZHANG Yingzhe, YANG Zhenlin. Research progress on biological indexes which predict the efficiency of neoadjuvant chemotherapy for breast cancer. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2017, 24(12): 1546-1550. doi: 10.7507/1007-9424.201704012 Copy

1.	Kaya AO, Coskun U, Buyukberber S, et al. Efficacy and toxicity of preoperative chemotherapy with docetaxel and epirubicin in locally advanced invasive breast cancer. J BUON, 2010, 15(2): 248-254.
2.	楊俊娥, 陸蘇, 劉紅. 不同新輔助化療方案治療乳腺癌近期療效觀察. 中國腫瘤臨床, 2011, 38(7): 405-408.
3.	Steger GG, Galid A, Gnant M, et al. Pathologic complete response with six compared with three cycles of neoadjuvant epirubicin plus docetaxel and granulocyte colony-stimulating factor in operable breast cancer: results of ABCSG-14. J Clin Oncol, 2007, 25(15): 2012-2018.
4.	Zhou Y, Ouyang T, Xie Y, et al. A single-center, randomized, parallel controlled study comparing the efficacy and safety aspects of three anthracycline-based regimens as neoadjuvant chemotherapy in primary breast cancer. Breast Cancer Res Treat, 2016, 157(3): 527-534.
5.	Houssami N, Macaskill P, von Minckwitz G, et al. Meta-analysis of the association of breast cancer subtype and pathologic complete response to neoadjuvant chemotherapy. Eur J Cancer, 2012, 48(18): 3342-3354.
6.	Rakovitch E, Nofech-Mozes S, Hanna W, et al. HER2/neu and Ki-67 expression predict non-invasive recurrence following breast-conserving therapy for ductal carcinoma in situ. Br J Cancer, 2012, 106(6): 1160-1165.
7.	劉揚, 龐達. 乳腺癌新輔助化療前后 Ki-67、HER-2、ER 和 PR 的變化與臨床緩解率的關系. 實用腫瘤學雜志, 2011, 25(5): 442-445.
8.	Liu Q, Wang XZ, Mu DB, et al. Correlation analysis of hormone receptors and the expressions of HER-2 and Ki-67 in breast cancer. Eur J Gynaecol Oncol, 2015, 36(1): 78-83.
9.	Mazouni C, Baggerly K, Hawke D, et al. Evaluation of changes in serum protein profiles during neoadjuvant chemotherapy in HER2-positive breast cancer using an LC-MALDI-TOF/MS procedure. Proteomics, 2010, 10(19): 3525-3532.
10.	Petit T, Wilt M, Velten M, et al. Comparative value of tumour grade, hormonal receptors, Ki-67, HER-2 and topoisomerase II alpha status as predictive markers in breast cancer patients treated with neoadjuvant anthracycline-based chemotherapy. Eur J Cancer, 2004, 40(2): 205-211.
11.	石陽, 李琦, 李蓉, 等. 局部進展期乳腺癌新輔助化療前后生物標志物表達變化與療效的相關性. 現代腫瘤醫學, 2016, 24(1): 59-63.
12.	Kinsella MD, Nassar A, Siddiqui MT, et al. Estrogen receptor (ER), progesterone receptor (PR), and HER2 expression pre-and post-neoadjuvant chemotherapy in primary breast carcinoma: a single institutional experience. Int J Clin Exp Pathol, 2012, 5(6): 530-536.
13.	Itoh M, Iwamoto T, Matsuoka J, et al. Estrogen receptor (ER) mRNA expression and molecular subtype distribution in ER-negative/progesterone receptor-positive breast cancers. Breast Cancer Res Treat, 2014, 143(2): 403-409.
14.	Makris A, Powles TJ, Allred DC, et al. Quantitative changes in cytological molecular markers during primary medical treatment of breast cancer: a pilot study. Breast Cancer Res Treat, 1999, 53(1): 51-59.
15.	van de Ven S, Smit VT, Dekker TJ, et al. Discordances in ER, PR and HER2 receptors after neoadjuvant chemotherapy in breast cancer. Cancer Treat Rev, 2011, 37(6): 422-430.
16.	Yang YF, Liao YY, Li LQ, et al. Changes in ER, PR and HER2 receptors status after neoadjuvant chemotherapy in breast cancer. Pathol Res Pract, 2013, 209(12): 797-802.
17.	Masuda H, Masuda N, Kodama Y, et al. Predictive factors for the effectiveness of neoadjuvant chemotherapy and prognosis in triple-negative breast cancer patients. Cancer Chemother Pharmacol, 2011, 67(4): 911-917.
18.	Yoshioka T, Hosoda M, Yamamoto M, et al. Prognostic significance of pathologic complete response and Ki67 expression after neoadjuvant chemotherapy in breast cancer. Breast Cancer, 2015, 22(2): 185-191.
19.	Ohno S, Chow LW, Sato N, et al. Randomized trial of preoperative docetaxel with or without capecitabine after 4 cycles of 5-fluorouracil-epirubicin-cyclophosphamide (FEC) in early-stage breast cancer: exploratory analyses identify Ki67 as a predictive biomarker for response to neoadjuvant chemotherapy. Breast Cancer Res Treat, 2013, 142(1): 69-80.
20.	謝菲, 周波, 曹迎明, 等. 不同生物學標志物對乳腺癌新輔助化療療效的預測價值. 中國癌癥雜志, 2010, 20(6): 453-455.
21.	Anelli A, Brentani RR, Gadelha AP, et al. Correlation of p53 status with outcome of neoadjuvant chemotherapy using paclitaxel and doxorubicin in stage ⅢB breast cancer. Ann Oncol, 2003, 14(3): 428-432.
22.	林奇, 陳慧玉, 劉洋, 等. 新輔助化療對乳腺癌患者 survivin、Ki-67、ER、C-erbB-2、p53 和腫瘤組織學分級的影響及其療效預測意義. 實用腫瘤雜志, 2010, 25(4): 400-404.
23.	DiGiovanna MP, Stern DF, Edgerton S, et al. Influence of activation state of ErbB-2 (HER-2) on response to adjuvant cyclophosphamide, doxorubicin, and fluorouracil for stageⅡ, node-positive breast cancer: study 8541 from the Cancer and Leukemia Group B. J Clin Oncol, 2008, 26(14): 2364-2372.
24.	Kute TE, Quadri Y, Muss H, et al. Flow cytometry in node-positive breast cancer: cancer and leukemia group B protocol 8869. Cytometry, 1995, 22(4): 297-306.
25.	Liu X, Holstege H, van der Gulden H, et al. Somatic loss of BRCA1 and p53 in mice induces mammary tumors with features of human BRCA1-mutated basal-like breast cancer. Proc Natl Acad Sci U S A, 2007, 104(29): 12111-12116.
26.	Andre F, Pusztai L. Heterogeneity of breast cancer among patients and implications for patient selection for adjuvant chemotherapy. Pharm Res, 2006, 23(9): 1951-1958.
27.	Azab B, Shah N, Radbel J, et al. Pretreatment neutrophil/lymphocyte ratio is superior to platelet/lymphocyte ratio as a predictor of long-term mortality in breast cancer patients. Med Oncol, 2013, 30(1): 432.
28.	Noh H, Eomm M, Han A. Usefulness of pretreatment neutrophil to lymphocyte ratio in predicting disease-specific survival in breast cancer patients. J Breast Cancer, 2013, 16(1): 55-59.
29.	Azab B, Bhatt VR, Phookan J, et al. Usefulness of the neutrophil-to-lymphocyte ratio in predicting short-and long-term mortality in breast cancer patients. Ann Surg Oncol, 2012, 19(1): 217-224.
30.	Malietzis G, Giacometti M, Kennedy RH, et al. The emerging role of neutrophil to lymphocyte ratio in determining colorectal cancer treatment outcomes: a systematic review and meta-analysis. Ann Surg Oncol, 2014, 21(12): 3938-3946.
31.	Templeton AJ, McNamara MG, ?eruga B, et al. Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. J Natl Cancer Inst, 2014, 106(6): dju124.
32.	Asano Y, Kashiwagi S, Onoda N, et al. Predictive value of neutrophil/lymphocyte ratio for efficacy of preoperative chemotherapy in triple-negative breast cancer. Ann Surg Oncol, 2016, 23(4): 1104-1110.
33.	Hung HY, Chen JS, Yeh CY, et al. Effect of preoperative neutrophil-lymphocyte ratio on the surgical outcomes of stage Ⅱ colon cancer patients who do not receive adjuvant chemotherapy. Int J Colorectal Dis, 2011, 26(8): 1059-1065.
34.	Mallappa S, Sinha A, Gupta S. Preoperative neutrophil to lymphocyte ratio >5 is a prognostic factor for recurrent colorectal cancer. Colorectal Dis, 2013, 15(3): 323-328.
35.	Chen Y, Chen K, Xiao X, et al. Pretreatment neutrophil-to-lymphocyte ratio is correlated with response to neoadjuvant chemotherapy as an independent prognostic indicator in breast cancer patients: a retrospective study. BMC Cancer, 2016, 16: 320.
36.	楊超, 蔡愛珍, 郗洪慶, 等. 胃癌新輔助化療前血小板水平與療效的關系. 中華普通外科雜志, 2016, 31(7): 593-595.
37.	Sansanayudh N, Anothaisintawee T, Muntham D, et al. Mean platelet volume and coronary artery disease: a systematic review and meta-analysis. Int J Cardiol, 2014, 175(3): 433-440.
38.	Mutlu H, Ery?lmaz MK, Musri FY, et al. Mean platelet volume as an independent predictive marker for pathologic complete response after neoadjuvant chemotherapy in patients with locally advanced breast cancer. Asian Pac J Cancer Prev, 2016, 17(4): 2089-2092.
39.	Dirican A, Kucukzeybek Y, Erten C, et al. Prognostic and predictive value of hematologic parameters in patients with metastatic renal cell carcinoma: second line sunitinib treatment following IFN-alpha. Asian Pac J Cancer Prev, 2013, 14(3): 2101-2105.
40.	Tuncel T, Ozgun A, Emirzeoglu L, et al. Mean platelet volume as a prognostic marker in metastatic colorectal cancer patients treated with bevacizumab-combined chemotherapy. Asian Pac J Cancer Prev, 2014, 15(15): 6421-6423.
41.	Inagaki N, Kibata K, Tamaki T, et al. Prognostic impact of the mean platelet volume/platelet count ratio in terms of survival in advanced non-small cell lung cancer. Lung Cancer, 2014, 83(1): 97-101.

1. Kaya AO, Coskun U, Buyukberber S, et al. Efficacy and toxicity of preoperative chemotherapy with docetaxel and epirubicin in locally advanced invasive breast cancer. J BUON, 2010, 15(2): 248-254.
2. 楊俊娥, 陸蘇, 劉紅. 不同新輔助化療方案治療乳腺癌近期療效觀察. 中國腫瘤臨床, 2011, 38(7): 405-408.
3. Steger GG, Galid A, Gnant M, et al. Pathologic complete response with six compared with three cycles of neoadjuvant epirubicin plus docetaxel and granulocyte colony-stimulating factor in operable breast cancer: results of ABCSG-14. J Clin Oncol, 2007, 25(15): 2012-2018.
4. Zhou Y, Ouyang T, Xie Y, et al. A single-center, randomized, parallel controlled study comparing the efficacy and safety aspects of three anthracycline-based regimens as neoadjuvant chemotherapy in primary breast cancer. Breast Cancer Res Treat, 2016, 157(3): 527-534.
5. Houssami N, Macaskill P, von Minckwitz G, et al. Meta-analysis of the association of breast cancer subtype and pathologic complete response to neoadjuvant chemotherapy. Eur J Cancer, 2012, 48(18): 3342-3354.
6. Rakovitch E, Nofech-Mozes S, Hanna W, et al. HER2/neu and Ki-67 expression predict non-invasive recurrence following breast-conserving therapy for ductal carcinoma in situ. Br J Cancer, 2012, 106(6): 1160-1165.
7. 劉揚, 龐達. 乳腺癌新輔助化療前后 Ki-67、HER-2、ER 和 PR 的變化與臨床緩解率的關系. 實用腫瘤學雜志, 2011, 25(5): 442-445.
8. Liu Q, Wang XZ, Mu DB, et al. Correlation analysis of hormone receptors and the expressions of HER-2 and Ki-67 in breast cancer. Eur J Gynaecol Oncol, 2015, 36(1): 78-83.
9. Mazouni C, Baggerly K, Hawke D, et al. Evaluation of changes in serum protein profiles during neoadjuvant chemotherapy in HER2-positive breast cancer using an LC-MALDI-TOF/MS procedure. Proteomics, 2010, 10(19): 3525-3532.
10. Petit T, Wilt M, Velten M, et al. Comparative value of tumour grade, hormonal receptors, Ki-67, HER-2 and topoisomerase II alpha status as predictive markers in breast cancer patients treated with neoadjuvant anthracycline-based chemotherapy. Eur J Cancer, 2004, 40(2): 205-211.
11. 石陽, 李琦, 李蓉, 等. 局部進展期乳腺癌新輔助化療前后生物標志物表達變化與療效的相關性. 現代腫瘤醫學, 2016, 24(1): 59-63.
12. Kinsella MD, Nassar A, Siddiqui MT, et al. Estrogen receptor (ER), progesterone receptor (PR), and HER2 expression pre-and post-neoadjuvant chemotherapy in primary breast carcinoma: a single institutional experience. Int J Clin Exp Pathol, 2012, 5(6): 530-536.
13. Itoh M, Iwamoto T, Matsuoka J, et al. Estrogen receptor (ER) mRNA expression and molecular subtype distribution in ER-negative/progesterone receptor-positive breast cancers. Breast Cancer Res Treat, 2014, 143(2): 403-409.
14. Makris A, Powles TJ, Allred DC, et al. Quantitative changes in cytological molecular markers during primary medical treatment of breast cancer: a pilot study. Breast Cancer Res Treat, 1999, 53(1): 51-59.
15. van de Ven S, Smit VT, Dekker TJ, et al. Discordances in ER, PR and HER2 receptors after neoadjuvant chemotherapy in breast cancer. Cancer Treat Rev, 2011, 37(6): 422-430.
16. Yang YF, Liao YY, Li LQ, et al. Changes in ER, PR and HER2 receptors status after neoadjuvant chemotherapy in breast cancer. Pathol Res Pract, 2013, 209(12): 797-802.
17. Masuda H, Masuda N, Kodama Y, et al. Predictive factors for the effectiveness of neoadjuvant chemotherapy and prognosis in triple-negative breast cancer patients. Cancer Chemother Pharmacol, 2011, 67(4): 911-917.
18. Yoshioka T, Hosoda M, Yamamoto M, et al. Prognostic significance of pathologic complete response and Ki67 expression after neoadjuvant chemotherapy in breast cancer. Breast Cancer, 2015, 22(2): 185-191.
19. Ohno S, Chow LW, Sato N, et al. Randomized trial of preoperative docetaxel with or without capecitabine after 4 cycles of 5-fluorouracil-epirubicin-cyclophosphamide (FEC) in early-stage breast cancer: exploratory analyses identify Ki67 as a predictive biomarker for response to neoadjuvant chemotherapy. Breast Cancer Res Treat, 2013, 142(1): 69-80.
20. 謝菲, 周波, 曹迎明, 等. 不同生物學標志物對乳腺癌新輔助化療療效的預測價值. 中國癌癥雜志, 2010, 20(6): 453-455.
21. Anelli A, Brentani RR, Gadelha AP, et al. Correlation of p53 status with outcome of neoadjuvant chemotherapy using paclitaxel and doxorubicin in stage ⅢB breast cancer. Ann Oncol, 2003, 14(3): 428-432.
22. 林奇, 陳慧玉, 劉洋, 等. 新輔助化療對乳腺癌患者 survivin、Ki-67、ER、C-erbB-2、p53 和腫瘤組織學分級的影響及其療效預測意義. 實用腫瘤雜志, 2010, 25(4): 400-404.
23. DiGiovanna MP, Stern DF, Edgerton S, et al. Influence of activation state of ErbB-2 (HER-2) on response to adjuvant cyclophosphamide, doxorubicin, and fluorouracil for stageⅡ, node-positive breast cancer: study 8541 from the Cancer and Leukemia Group B. J Clin Oncol, 2008, 26(14): 2364-2372.
24. Kute TE, Quadri Y, Muss H, et al. Flow cytometry in node-positive breast cancer: cancer and leukemia group B protocol 8869. Cytometry, 1995, 22(4): 297-306.
25. Liu X, Holstege H, van der Gulden H, et al. Somatic loss of BRCA1 and p53 in mice induces mammary tumors with features of human BRCA1-mutated basal-like breast cancer. Proc Natl Acad Sci U S A, 2007, 104(29): 12111-12116.
26. Andre F, Pusztai L. Heterogeneity of breast cancer among patients and implications for patient selection for adjuvant chemotherapy. Pharm Res, 2006, 23(9): 1951-1958.
27. Azab B, Shah N, Radbel J, et al. Pretreatment neutrophil/lymphocyte ratio is superior to platelet/lymphocyte ratio as a predictor of long-term mortality in breast cancer patients. Med Oncol, 2013, 30(1): 432.
28. Noh H, Eomm M, Han A. Usefulness of pretreatment neutrophil to lymphocyte ratio in predicting disease-specific survival in breast cancer patients. J Breast Cancer, 2013, 16(1): 55-59.
29. Azab B, Bhatt VR, Phookan J, et al. Usefulness of the neutrophil-to-lymphocyte ratio in predicting short-and long-term mortality in breast cancer patients. Ann Surg Oncol, 2012, 19(1): 217-224.
30. Malietzis G, Giacometti M, Kennedy RH, et al. The emerging role of neutrophil to lymphocyte ratio in determining colorectal cancer treatment outcomes: a systematic review and meta-analysis. Ann Surg Oncol, 2014, 21(12): 3938-3946.
31. Templeton AJ, McNamara MG, ?eruga B, et al. Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. J Natl Cancer Inst, 2014, 106(6): dju124.
32. Asano Y, Kashiwagi S, Onoda N, et al. Predictive value of neutrophil/lymphocyte ratio for efficacy of preoperative chemotherapy in triple-negative breast cancer. Ann Surg Oncol, 2016, 23(4): 1104-1110.
33. Hung HY, Chen JS, Yeh CY, et al. Effect of preoperative neutrophil-lymphocyte ratio on the surgical outcomes of stage Ⅱ colon cancer patients who do not receive adjuvant chemotherapy. Int J Colorectal Dis, 2011, 26(8): 1059-1065.
34. Mallappa S, Sinha A, Gupta S. Preoperative neutrophil to lymphocyte ratio >5 is a prognostic factor for recurrent colorectal cancer. Colorectal Dis, 2013, 15(3): 323-328.
35. Chen Y, Chen K, Xiao X, et al. Pretreatment neutrophil-to-lymphocyte ratio is correlated with response to neoadjuvant chemotherapy as an independent prognostic indicator in breast cancer patients: a retrospective study. BMC Cancer, 2016, 16: 320.
36. 楊超, 蔡愛珍, 郗洪慶, 等. 胃癌新輔助化療前血小板水平與療效的關系. 中華普通外科雜志, 2016, 31(7): 593-595.
37. Sansanayudh N, Anothaisintawee T, Muntham D, et al. Mean platelet volume and coronary artery disease: a systematic review and meta-analysis. Int J Cardiol, 2014, 175(3): 433-440.
38. Mutlu H, Ery?lmaz MK, Musri FY, et al. Mean platelet volume as an independent predictive marker for pathologic complete response after neoadjuvant chemotherapy in patients with locally advanced breast cancer. Asian Pac J Cancer Prev, 2016, 17(4): 2089-2092.
39. Dirican A, Kucukzeybek Y, Erten C, et al. Prognostic and predictive value of hematologic parameters in patients with metastatic renal cell carcinoma: second line sunitinib treatment following IFN-alpha. Asian Pac J Cancer Prev, 2013, 14(3): 2101-2105.
40. Tuncel T, Ozgun A, Emirzeoglu L, et al. Mean platelet volume as a prognostic marker in metastatic colorectal cancer patients treated with bevacizumab-combined chemotherapy. Asian Pac J Cancer Prev, 2014, 15(15): 6421-6423.
41. Inagaki N, Kibata K, Tamaki T, et al. Prognostic impact of the mean platelet volume/platelet count ratio in terms of survival in advanced non-small cell lung cancer. Lung Cancer, 2014, 83(1): 97-101.

Previous Article
The current research status of gastric schwannoma
Next Article
膽石性十二指腸梗阻 1 例報道

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Research progress on biological indexes which predict the efficiency of neoadjuvant chemotherapy for breast cancer

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content